ABSTRACT
At present there are up to 40 licensed biopharmaceuticals produced from mammalian cell bioprocesses (Molowa and Mazanet, 2003; Pavlou, 2003; Walsh, 2003). These are recombinant proteins, monoclonal antibodies and nucleic acid-based products.
